A living biobank of matched pairs of patient-derived xenografts and organoids for cancer pharmacology
PLOS ONE · 2023
DOI: 10.1371/journal.pone.0279821 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Xiaoxi Xu und 23 weiteren Autor:innen. Beteiligte Einrichtung: Crown Bioscience Inc., Beijing, China. Hauptthemen laut MEDLINE: Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Patient-derived tumor xenograft (PDX)/organoid (PDO), driven by cancer stem cells (CSC), are considered the most predictive models for translational oncology. Large PDX collections reflective of patient populations have been created and used extensively to test various investigational therapies, including population-trials as surrogate subjects in vivo . PDOs are recognized as in vitro surrogates for patients amenable for high-throughput screening (HTS). We have built a biobank of carcinoma PDX-derived organoids (PDXOs) by converting an existing PDX library and confirmed high degree of similarities between PDXOs and parental PDXs in genomics, histopathology and pharmacology, suggesting “biological equivalence or interchangeability” between the two. Here we demonstrate the applications of PDXO biobank for HTS “matrix” screening for both lead compounds and indications, immune cell co-cultures for immune-therapies and engineering enables in vitro/in vivo imaging. This large biobank of >550 matched pairs of PDXs/PDXOs across different cancers could become powerful tools for the future cancer drug discovery.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Crown Bioscience Inc., Beijing, China.
- Crown Bioscience Inc., San Diego, California, United States of America.
- Crown Bioscience Inc., Taicang City, Jiangsu, China.
- Shanghai Yihao Biological Technology, Xuhui District, Shanghai, China.
- Suzhou NeoLogics Bioscience Co, LTD, Suzhou, China.
- Hubrecht Organoid Technology (HUB), Utrecht, The Netherlands.
ORCID-Profile: Rajendra Kumari, Qi-Xiang Li
Zitieren
APA
Xu, X., Kumari, R., Zhou, J., Chen, J., Mao, B., Wang, J., Zheng, M., Tu, X., An, X., Chen, X., Zhang, L., Tian, X., Wang, H., Dong, X., Bao, Z., Guo, S., Ouyang, X., Shang, L., Wang, F., …, & Li, Q. X. (2023). A living biobank of matched pairs of patient-derived xenografts and organoids for cancer pharmacology. PLOS ONE. https://doi.org/10.1371/journal.pone.0279821
Vancouver
Xu X, Kumari R, Zhou J, Chen J, Mao B, Wang J, et al. A living biobank of matched pairs of patient-derived xenografts and organoids for cancer pharmacology. PLOS ONE. 2023. doi:10.1371/journal.pone.0279821
BibTeX
@article{Xu2023,
author = {Xu, Xiaoxi and Kumari, Rajendra and Zhou, Jun and Chen, Jing and Mao, Binchen and Wang, Jingjing and Zheng, Meiling and Tu, Xiaolong and An, Xiaoyu and Chen, Xiaobo and Zhang, Likun and Tian, Xiaoli and Wang, Haojie and Dong, Xin and Bao, Zhengzheng and Guo, Sheng and Ouyang, Xuesong and Shang, Limei and Wang, Fei and Yan, Xuefei and Zhang, Rui and Vries, Robert G J and Clevers, Hans and Li, Qi-Xiang},
title = {A living biobank of matched pairs of patient-derived xenografts and organoids for cancer pharmacology},
journal = {PLOS ONE},
year = {2023},
doi = {10.1371/journal.pone.0279821}
}
EUVIMED